Increase in glycated haemoglobin concentrations after unwarranted prescription changes
Abstract
Recently Khouri et al performed a disproportionality analysis of the WHO database of individual case safety reports, suggesting that amputations from use of SGLT2-inhibitors could be a class effect, of low prevalence, and not restricted to canagliflozin.1 This publication should help alleviate the fears of patients taking canagliflozin, and result in a change in prescribing behaviour. Prior to this report, the discovery of the association of amputations with canagliflozin was described in the CANVAS study2 and subsequently, promulgation of those results by plaintiff lawyers in television commercials, resulted in many patients refusing to continue canagliflozin therapy and demanding an alternative. In our practices that alternative was empagliflozin. We conducted a small non-randomized retrospective study to establish if the change from canagliflozin to empagliflozin had resulted in worsening in glycemic control. This article is protected by copyright. All rights reserved.
Read the paper
Related studies
- Strategy for Mitigating DKA Risk in Patients with Type 1 Diabetes on Adjunctive Treatment with SGLT Inhibitors: A STICH Protocol
- Glucoraphanin: a broccoli sprout extract that ameliorates obesity-induced inflammation and insulin resistance
- SGLT2 Inhibitors in Heart Failure: Targeted Metabolomics and Energetic Metabolism
- Mechanisms of blood pressure reduction with sodium-glucose co-transporter 2 (SGLT2) inhibitors
- Sodium-glucose cotransporter inhibitors: beyond glycaemic control
- Decoding the effects of SGLT2 inhibitors on cardiac arrhythmias in heart failure
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.